- Sustained sluggish market demand and intense competition.
- Risks associated with industry policy changes (adjustments to the Medical Insurance Catalogue, the promotion of Consistency Evaluation and lowering of the bid price).
- Risks associated with research and development of new drugs (uncertain approvals and market sales).
- Risk associated with lower price (downward pressure on drug prices due to tenders and industry policies).
- Risk associated with supply and price fluctuation of raw materials.
- Environmental risk (sewage, wasted gas and wasted residue generated during production).
SHANDONG XINHUA PHARMACEUTICAL COMPANY LIMITED
Greenhouse gas emissions & sustainability report data
Figures are as stated in the company's own report and may use different boundaries, units or methods (for example market-based vs location-based Scope 2), so compare with care.
📈 Emissions by Report Period
| Report period | Headline emissions figure reported |
|---|---|
| 2023 | 260.6K tCO2e/year (Scope I and II) |
| 2022 | 258.5K tCO2e/year |
| 2021 | 251.0K tCO2e |
Each row is the headline figure extracted from a different report; scope coverage and methodology can change between years.
✅ Reported Environmental Achievements
- No. 2 factory passed the FDA site audit with zero defects and successfully passed on-site audits by Brazil and that of the Health Department of Canada.
- Initiated the dual carbon strategy implementation plan.
- In the first half of 2024, the Group invested RMB10,434,5400 in environmental protection and paid RMB111,600 in environmental protection tax.